What do systematic reviews say?

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

The review found no eligible studies for this question.

• Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 129 participants
  Very low

Systemic antifungal vs placebo/no treatment

The review found no eligible studies for this question.

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Next‐generation ALK inhibitor vs crizotinib

It is very uncertain whether next‐generation ALK inhibitor changes health‐related quality of life: time to deterioration in composite… compared with crizotinib (very low certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 1.1 [0.72, 1.68]
  1 study · 303 participants
  Very low

Hearing aid vs sound generator

The review found no eligible studies for this question.

• Sound therapy (using amplification devices and/or sound generators) for tinnitus 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs chemoembolisation

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

E1B‐deleted (dl1520) adenovirus vs percutaneous alcohol injection

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Combination hearing aid vs hearing aid

The review found no eligible studies for this question.

• Sound therapy (using amplification devices and/or sound generators) for tinnitus 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found